MUSCLE VOLUME Z-SCORE IS LOWER IN HIGH-RISK PATIENTS AWAITING LT - INTERIM RESULTS FROM A LIVER TRANSPLANT WAITLIST NATURAL HISTORY STUDY

被引：0
|
作者：
Forsgren, Mikael Fredrik [1 ,2 ]
Lee, Seung [3 ]
Linge, Jennifer [1 ,2 ]
Kirkman, Danielle [4 ]
Patel, Vaishali [3 ]
Widholm, Per [2 ]
Roche, Geneva [4 ]
Kamal, Hiba [4 ]
Leinhard, Olof Dahlqvist [1 ,2 ]
Siddiqui, Mohammad S. [4 ]
机构：
[1] Linkoping Univ, Linkoping, Sweden
[2] Amra Med AB, Linkoping, Sweden
[3] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA
[4] Virginia Commonwealth Univ, Richmond, VA USA
来源：
HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
3090-A
引用
收藏
页码：S1401 / S1402
页数：2
相关论文
共 11 条
  • [1] IMAGING-BASED TEST FOR SARCOPENIA - INTERIM RESULTS FROM A LIVER TRANSPLANT WAITLIST NATURAL HISTORY STUDY
    Forsgren, Mikael Fredrik
    Bhati, Chandra
    Evans, Marie-Claire
    Kamal, Hiba
    Leinhard, Olof Dahlqvist
    Siddiqui, Mohammad Shadab
    HEPATOLOGY, 2022, 76 : S481 - S482
  • [2] Body composition and muscle composition phenotypes in patients on waitlist and shortly after liver transplant - results from a pilot study
    Forsgren, Mikael F.
    Pine, Stewart
    Harrington, Claire Royalle
    Gregory, Dyanna
    Petersson, Mikael
    Rinella, Mary
    Leinhard, Olof Dahlqvist
    VanWagner, Lisa B.
    BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [3] Achievement of guideline-defined treatment goals in high-risk patients for cardiovascular events in primary care. Results from the CoRiMa study using the SCORE-Germany risk calculator
    Geller, J. C.
    Keil, U.
    Prien, M.
    Brosz, M.
    Kropf, S.
    Hallauer, J.
    Cassens, S.
    Pels, K.
    EUROPEAN HEART JOURNAL, 2006, 27 : 673 - 674
  • [4] Interim results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
    Li, Zhiyong
    He, Liru
    Yao, Kai
    Ye, Yunlin
    Li, Xiangdong
    Qin, Zike
    Han, Hui
    Zhou, Fangjian
    Liu, Zhuowei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] MUSCLE FAT INFILTRATION, A POTENTIAL RISK MARKER, INCREASES RAPIDLY IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS - INTERIM RESULTS FROM THE PROSPECTIVE MULTI-CENTER CIRRHOSIS COHORT STUDY ACCESS-ESLD
    Forsgren, Mikael Fredrik
    Balkhed, Wile
    Nasr, Patrik
    Sjogren, Daniel
    Linge, Jennifer
    Cederborg, Anna
    Holmberg, Markus
    Dahlstrom, Nils
    Stjernman, Henrik
    Rejler, Martin
    Kechagias, Stergios
    Leinhard, Olof Dahlqvist
    Ekstedt, Mattias
    HEPATOLOGY, 2023, 78 : S1400 - S1401
  • [6] Is early single-dose instillation of epirubicin able to improve BCG efficacy in non-muscle invasive high-risk bladder cancer patients? Results from a prospective, randomised, double-blind and controlled study
    Bartoletti, R.
    Cai, T.
    Mondaini, W.
    Nesi, G.
    Mazzoli, S.
    Boddi, V.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 177 - 177
  • [7] Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
    Li, Zhiyong
    He, Liru
    Li, Xiangdong
    Yao, Kai
    Liu, Yang
    Qin, Zike
    Ye, Yunlin
    Zhou, Fangjian
    Liu, Zhuowei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [8] Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HRNMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.
    Catto, James W. F.
    Ben Tran
    Master, Viraj A.
    Roupret, Morgan
    Pignot, Geraldine
    Tubaro, Andrea
    Shimizu, Nobuaki
    Vasdev, Nikhil
    Gschwend, Jurgen E.
    Loriot, Yohann
    Nishiyama, Hiroyuki
    Redorta, Joan
    Daneshmand, Siamak
    Miura, Yuji
    Naini, Vahid
    Crow, Lauren
    Triantos, Spyros
    Baig, Mahadi
    Steinberg, Gary D.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [9] Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2-trial
    Harbeck, Nadia
    Gluz, Oleg
    Kuemmel, Sherko
    Christgen, Matthias
    Braun, Michael
    Aktas, Bahriye
    Luedtke-Heckenkamp, Kerstin
    Forstbauer, Helmut
    Grischke, Eva-Maria
    Schumacher, Claudia
    Darsow, Maren
    Krauss, Katja
    Nuding, Benno
    Thill, Marc
    Potenberg, Jochem
    Uleer, Christoph
    Warm, Mathias
    Fischer, Hans H.
    Malter, Wolfram
    Hauptmann, Michael
    Kates, Ronald
    Graeser, Monika
    Wuerstlein, Rachel
    Shak, Steve
    Baehner, Rick
    Kreipe, Hans
    Nitz, Ulrike
    CANCER RESEARCH, 2021, 81 (04)
  • [10] Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2)
    Harrison, Claire N.
    Schaap, Nicolaas P. M.
    Zweegman, Sonja
    Jourdan, Eric
    Kiladjian, Jean-Jacques
    Cervantes, Francisco
    Niederwieser, Dietger
    Cortes, Jorge E.
    Passamonti, Francesco
    Reiter, Andreas
    Recher, Christian
    Doehner, Konstanze
    Heidel, Florian H.
    Silver, Richard T.
    Winton, Elliott F.
    Gupta, Vikas
    Ojeda, Emilio
    Gisslinger, Heinz
    Vannucchi, Alessandro M.
    Talpaz, Moshe
    Zhang, Jenny
    Shi, Weiliang
    Mesa, Ruben A.
    BLOOD, 2013, 122 (21)
12